We are live on ! Find out more
TCON

TRACON Pharmaceuticals, Inc. Common Stock
TCON

Delisted

TCON was delisted on the 27th of June, 2024.

Back to rankings

33 hedge funds and large institutions have $16.4M invested in TRACON Pharmaceuticals, Inc. Common Stock in 2022 Q3 according to their latest regulatory filings, with 4 funds opening new positions, 4 increasing their positions, 7 reducing their positions, and 2 closing their positions.

New
Increased
Maintained
Reduced
Closed

100% more first-time investments, than exits

New positions opened: 4 | Existing positions closed: 2

6% more funds holding

Funds holding: 31 → 33 (+2)

0% more funds holding in top 10

Funds holding in top 10: 1 → 1 (0)

17% less capital invested

Capital invested by funds: $19.7M → $16.4M (-$3.29M)

43% less repeat investments, than reductions

Existing positions increased: 4 | Existing positions reduced: 7

Holders
33
Holders Change
+2
Holders Change %
+6.45%
% of All Funds
0.57%
Holding in Top 10
1
Holding in Top 10 Change
–
Holding in Top 10 Change %
–
% of All Funds
0.02%
New
4
Increased
4
Reduced
7
Closed
2
Calls
$52K
Puts
–
Net Calls
+$52K
Net Calls Change
-$26K

Top Buyers

Rank Fund Capital Flow
1
OM
Opaleye Management
Massachusetts
+$123K
2
Citadel Advisors
Citadel Advisors
Florida
+$39.7K
3
CL
CSS LLC
Illinois
+$38.4K
4
Renaissance Technologies
Renaissance Technologies
New York
+$29.2K
5
Susquehanna International Group
Susquehanna International Group
Pennsylvania
+$24.7K

Top Sellers

Rank Fund Capital Flow
1
Two Sigma Advisers
Two Sigma Advisers
New York
-$114K
2
Millennium Management
Millennium Management
New York
-$77.9K
3
IC
Ikarian Capital
Texas
-$44.5K
4
Jane Street
Jane Street
New York
-$20K
5
BFM
Boothbay Fund Management
New York
-$18.1K
Name Holding Trade Value Shares
Change 		Change in
Stake
OM
1
Opaleye Management
Massachusetts
$7M +$123K +3,234 +2%
IC
2
Ikarian Capital
Texas
$4.62M -$44.5K -1,166 -0.8%
Vanguard Group
3
Vanguard Group
Pennsylvania
$986K – – –
LA
4
Linden Advisors
New York
$760K – – –
NMC
5
NEA Management Company
Maryland
$579K – – –
BlackRock
6
BlackRock
New York
$507K -$2.56K -67 -0.4%
BFM
7
Boothbay Fund Management
New York
$432K -$18.1K -473 -4%
Geode Capital Management
8
Geode Capital Management
Massachusetts
$260K – – –
Two Sigma Advisers
9
Two Sigma Advisers
New York
$168K -$114K -2,990 -37%
TI
10
Telemetry Investments
New York
$162K -$5.73K -150 -3%
JJ
11
Johnson & Johnson
New Jersey
$140K – – –
State Street
12
State Street
Massachusetts
$126K – – –
Renaissance Technologies
13
Renaissance Technologies
New York
$113K +$29.2K +765 +29%
Bank of New York Mellon
14
Bank of New York Mellon
New York
$112K – – –
DY
15
Dowling & Yahnke
California
$79K – – –
CL
16
CSS LLC
Illinois
$76K +$38.4K +1,005 +80%
Two Sigma Investments
17
Two Sigma Investments
New York
$67K -$2.1K -55 -3%
Millennium Management
18
Millennium Management
New York
$57K -$77.9K -2,041 -54%
ACM
19
ACT Capital Management
Pennsylvania
$48K – – –
Citadel Advisors
20
Citadel Advisors
Florida
$35K +$39.7K +1,041 New
XSC
21
X-Square Capital
Puerto Rico
$30K – – –
Northern Trust
22
Northern Trust
Illinois
$29K – – –
H
23
HoyleCohen
California
$22K – – –
Susquehanna International Group
24
Susquehanna International Group
Pennsylvania
$22K +$24.7K +646 New
TRCT
25
Tower Research Capital (TRC)
New York
$11K +$9.96K +261 +322%
1
2

TCON Hedge Fund Activity: Q3 2022 in Review

33 of the 5,805 institutional investors tracked by Wall St. Rank reported a position in TRACON Pharmaceuticals, Inc. Common Stock (TCON) for Q3 2022, worth a combined $16.4M — down 17% from $19.7M a quarter earlier.

Buyers outnumbered sellers: 4 funds opened new TCON positions and 2 closed out — a net gain of 2 holders — while 4 added to existing stakes and 7 trimmed.

The largest buyer was Opaleye Management, adding an estimated $123K. The largest seller was Two Sigma Advisers, cutting an estimated $114K.

  • 33 institutional investors held TRACON Pharmaceuticals, Inc. Common Stock (TCON) as of Q3 2022, up from 31 in Q2 2022.
  • Funds reported $16.4M of TRACON Pharmaceuticals, Inc. Common Stock stock for Q3 2022, down 17% quarter-over-quarter.
  • 4 funds opened new TRACON Pharmaceuticals, Inc. Common Stock positions in Q3 2022 and 2 closed out, a net change of +2 holders.
  • The largest TRACON Pharmaceuticals, Inc. Common Stock buyer in Q3 2022 was Opaleye Management, an estimated $123K added.
  • The largest TRACON Pharmaceuticals, Inc. Common Stock seller in Q3 2022 was Two Sigma Advisers, an estimated $114K sold.

Based on aggregated 13F filings for Q3 2022.